ACM
CBIO

ADAR1 Capital Management’s Crescent Biopharma CBIO Stock Holding History

ADAR1 Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,350
Closed -$38K – 305
2024
Q2 		$38K Sell
1,350
-41
-3% -$4.26K 0.01% 199
2024
Q1 		$417K Buy
+1,391
New +$415K 0.09% 91

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management's CBIO Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Crescent Biopharma (CBIO) stake by 64% in Q2 2026, selling an estimated $625K and leaving 18,275 shares worth $329K. The position accounts for 0.02% of the portfolio, ranked #232.

ADAR1 Capital Management first reported a position in CBIO in Q2 2024 and has held it in 6 quarters since. The position peaked at $7.19M in Q4 2025. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • ADAR1 Capital Management held 18,275 shares of Crescent Biopharma worth $329K as of Q2 2026.
  • ADAR1 Capital Management sold 31,998 Crescent Biopharma shares in Q2 2026, an estimated $625K.
  • Crescent Biopharma made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #232 holding.
  • ADAR1 Capital Management first reported a position in Crescent Biopharma in Q2 2024 and has held it in 6 quarters since.
  • ADAR1 Capital Management's Crescent Biopharma position peaked at $7.19M in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.